SUMO-Fused expression and characterization of Heparinase I from Bacteroides thetaiotaomicron
Author:
  • Article
  • | |
  • Metrics
  • |
  • Reference [29]
  • |
  • Related [20]
  • | | |
  • Comments
    Abstract:

    [Objective] To clone and recombinant express the gene Heparinase I from Bacteroides thetaiotaomicron, and then characterize the recombinant SUMO-Bt-HepI and Bt-HepI. [Methods] Codon optimization was done on the gene sequence of B. thetaiotaomicron heparinase I. The target gene was obtained by PCR amplification, inserted into the expression vectors pET-28a and pE-SUMO, and then transformed into E. coli Rosetta (DE3) to obtain recombinant products Bt-HepI and SUMO-Bt-HepI. Heparin sodium was used as substrate to study the enzymatic properties of the recombinant proteins. [Results] SDS-PAGE analysis showed that the molecular weights of Bt-HepI and SUMO-Bt-HepI were about 42.5 kDa and 55 kDa, respectively. Compared with Bt-HepI, the specific enzyme activity of Heparinase I increased by 48.9% after fusion SUMO-Tag. The enzymological properties showed that the optimum pH and temperature of Bt-HepI and SUMO-Bt-HepI were pH 9 and 45℃, and both recombinant enzymes were stable at pH 5-9, while the acid resistance of SUMO-Bt-HepI was obviously higher than Bt-HepI when the pH value was lower than 5. Besides, SUMO-Bt-HepI also showed higher activities than Bt-HepI under 50℃. In addition, Ca2+ and Mg2+ have obvious promoting effect on the recombinant heparinase I, while Cu2+, Mn2+ and Zn2+ show certain inhibiting effect, suggesting that in addition to the well-known Ca2+ binding site, Mg2+ binding sites may aslo exist in the structure of B. thetaiotaomicron Heparinase I. [Conclusion] Recombinant Heparinase I in B. thetaiotaomicron using SUMO fusion system significantly improved its specific enzyme activity for potential production and application.

    Reference
    [1] Witczak ZJ, Nieforth KA. Carbohydrates in drug design. European Journal of Medicinal Chemistry, 1997, 32(11):842.
    [2] Galliher PM, Cooney CL, Langer R, Linhardt RJ. Heparinase production by Flavobacterium heparinum. Applied and Environmental Microbiology, 1981, 41(2):360-365.
    [3] Kim BT, Kim WS, Kim YS, Linhardt RJ, Kim DH. Purification and characterization of a novel heparinase from Bacteroides stercoris HJ-15. The Journal of Biochemistry, 2000, 128(2):323-328.
    [4] Yoshida E, Sakai K, Tokuyama S, Miyazono H, Maruyama H, Morikawa K. Purification and characterization of heparinase that degrades both heparin and heparan sulfate from Bacillus circulans. Bioscience, Biotechnology, and Biochemistry, 2002, 66(5):1181-1184.
    [5] Yang VC, Linhardt RJ, Bernstein H, Cooney CL, Langer R. Purification and characterization of heparinase from Flavobacterium heparinum. Journal of Biological Chemistry, 1985, 260(3):1849-1857.
    [6] Sasisekharan R, Moses MA, Nugent MA, Cooney CL, Langer R. Heparinase inhibits neovascularization. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91(4):1524-1528.
    [7] Ernst S, Venkataraman G, Winkler S, Godavarti R, Langer R, Cooney CL, Sasisekharan R. Expression in Escherichia coli, purification and characterization of heparinase I from Flavobacterium heparinum. Biochemical Journal, 1996, 315(2):589-597.
    [8] Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest, 2001, 119(1):64S-94S.
    [9] Qureshi A, Perera A. Low molecular weight heparin versus unfractionated heparin in the management of cerebral venous thrombosis:A systematic review and meta-analysis. Annals of Medicine and Surgery, 2017, 17:22-26.
    [10] Welsby IJ, Newman MF, Phillips-Bute B, Messier RH, Kakkis ED, Stafford-Smith M. Hemodynamic changes after protamine administration:association with mortality after coronary artery bypass surgery. Anesthesiology, 2005, 102(2):308-314.
    [11] Guerrini M, Beccati D, Shriver Z, Naggi A, Viswanathan K, Bisio A, Capila I, Lansing JC, Guglieri S, Fraser B, Al-Hakim A, Gunay NS, Zhang ZQ, Robinson L, Buhse L, Nasr M, Woodcock J, Langer R, Venkataraman G, Linhardt RJ, Casu B, Torri G, Sasisekharan R. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nature Biotechnology, 2008, 26(6):669-675.
    [12] Aich U, Shriver Z, Tharakaraman K, Raman R, Sasisekharan R. Competitive inhibition of heparinase by persulfonated glycosaminoglycans:a tool to detect heparin contamination. Analytical Chemistry, 2011, 83(20):7815-7822.
    [13] Ameer GA, Harmon W, Sasisekharan R, Langer R. Investigation of a whole blood fluidized bed Taylor-Couette flow device for enzymatic heparin neutralization. Biotechnology and Bioengineering, 1999, 62(5):602-608.
    [14] Sasisekharan R, Bulmer M, Moremen KW, Cooney CL, Langer R. Cloning and expression of heparinase I gene from Flavobacterium heparinum. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90(8):3660-3664.
    [15] Shpigel E, Goldlust A, Efroni G, Avraham A, Eshel A, Dekel M, Shoseyov O. Immobilization of recombinant heparinase I fused to cellulose-binding domain. Biotechnology and Bioengineering, 1999, 65(1):17-23.
    [16] Ling CF, Zhang JY, Lin DQ, Tao AL. Approaches for the generation of active papain-like cysteine proteases from inclusion bodies of Escherichia coli. World Journal of Microbiology and Biotechnology, 2015, 31(5):681-690.
    [17] Kapust RB, Waugh DS. Escherichia coli maltose-binding protein is uncommonly effective at promoting the solubility of polypeptides to which it is fused. Protein Science, 1999, 8(8):1668-1674.
    [18] Chen Y, Xing XH, Ye FC, Kuang Y, Luo MF. Production of MBP-HepA fusion protein in recombinant Escherichia coli by optimization of culture medium. Biochemical Engineering Journal, 2007, 34(2):114-121.
    [19] Namvar S, Barkhordari F, Raigani M, Jahandar H, Nematollahi L, Davami F. Cloning and soluble expression of mature α-luffin from Luffa cylindrica in E. coli using SUMO fusion protein. Turkish Journal of Biology, 2018, 42:23-32.
    [20] Li JH, Han QX, Zhang T, Du J, Sun QQ, Pang YL. Expression of soluble native protein in Escherichia coli using a cold-shock SUMO tag-fused expression vector. Biotechnology Reports, 2018, 19:e00261.
    [21] Zhang J, Sun AY, Dong YG, Wei DZ. Recombinant production and characterization of SAC, the core domain of Par-4, by SUMO fusion system. Applied Biochemistry and Biotechnology, 2018, 184(4):1155-1167.
    [22] Hartwig S, Frister T, Alemdar S, Li Z, Scheper T, Beutel S. SUMO-fusion, purification, and characterization of a (+)-zizaene synthase from Chrysopogon zizanioides. Biochemical and Biophysical Research Communications, 2015, 458(4):883-889.
    [23] Bernstein H, Yang VC, Cooney CL, Langer R. Immobilized heparin lyase system for blood deheparinization. Methods in Enzymology, 1988, 137:515-529.
    [24] Huang J, Cao L, Guo WH, Yuan RX, Jia ZJ, Huang KH. Enhanced soluble expression of recombinant Flavobacterium heparinum heparinase I in Escherichia coli by fusing it with various soluble partners. Protein Expression and Purification, 2012, 83(2):169-176.
    [25] Xu SQ, Zhang XY, Qiu ML, Chen JH. Design and expression of recombinant heparanase I fused to chitin binding domain and SUMO-Tag. Chemical Industry and Engineering Progress, 2016, 35(S2):315-318. (in Chinese)许淑琴, 张轩月, 邱美玲, 陈敬华. ChBD和SUMO双功能融合肝素酶I的设计与表达. 化学进展, 2016, 35(S2):315-318.
    [26] Xu J, Bjursell MK, Himrod J, Deng S, Carmichael LK, Chiang HC, Hooper LV, Gordon JI. A genomic view of the human-Bacteroides thetaiotaomicron symbiosis. Science, 2003, 229(5615):2074-2076.
    [27] Luo YD, Huang XQ, McKeehan WL. High yield, purity and activity of soluble recombinant Bacteroides thetaiotaomicron GST-heparinase I from Escherichia coli. Archives of Biochemistry and Biophysics, 2007, 460(1):17-24.
    [28] Han YH, Garron ML, Kim HY, Kim WS, Zhang ZQ, Ryu KS, Shaya D, Xiao ZP, Cheong C, Kim YS, Linhardt RJ, Jeon YH, Cygler M. Structural snapshots of heparin depolymerization by heparin lyase I. Journal of Biological Chemistry, 2009, 284(49):34019-34027.
    [29] Ma XL, Wang ZS, Li SX, Shen Q, Yuan QS. Effect of CaCl2 as activity stabilizer on purification of heparinase I from Flavobacterium heparinum. Journal of Chromatography B, 2006, 843(2):209-215.
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation

Chuan Zhang, Yue Zhang, Xiaohu Ding, Zhongyuan Li, Yajian Song, Xuegang Luo. SUMO-Fused expression and characterization of Heparinase I from Bacteroides thetaiotaomicron. [J]. Acta Microbiologica Sinica, 2019, 59(7): 1318-1330

Copy
Share
Article Metrics
  • Abstract:865
  • PDF: 1858
  • HTML: 2351
  • Cited by: 0
History
  • Received:September 05,2018
  • Revised:November 11,2018
  • Online: July 02,2019
Article QR Code